标题
The Future of Somatostatin Receptor Ligands in Acromegaly
作者
关键词
-
出版物
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 107, Issue 2, Pages 297-308
出版商
The Endocrine Society
发表日期
2021-10-08
DOI
10.1210/clinem/dgab726
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Predictive and prognostic significance of tumour subtype, SSTR1‐5 and e‐cadherin expression in a well‐defined cohort of patients with acromegaly
- (2021) Jiri Soukup et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands
- (2021) Luiz Eduardo Wildemberg et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- New and emerging pharmacological treatment options for acromegaly
- (2021) Ximene Antunes et al. EXPERT OPINION ON PHARMACOTHERAPY
- Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective
- (2021) Federica Nista et al. Frontiers in Endocrinology
- Genetics of Acromegaly and Gigantism
- (2021) Anna Bogusławska et al. Journal of Clinical Medicine
- The effect of treatment on quality of life in patients with acromegaly: a prospective study
- (2020) T L C Wolters et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Clinical MEN-1 Among a Large Cohort of Patients With Acromegaly
- (2020) Lisa B Nachtigall et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Molecular profiling for acromegaly treatment: a validation study
- (2020) Manel Puig-Domingo et al. ENDOCRINE-RELATED CANCER
- T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly
- (2020) Eva C Coopmans et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
- (2020) Eva C Coopmans et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice
- (2020) Eliza B. Geer et al. BMC Endocrine Disorders
- Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?
- (2020) Cheol Ryong Ku et al. Endocrinology and Metabolism
- Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
- (2020) Susan L Samson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly
- (2020) Amy A. Swanson et al. Pituitary
- A Pituitary Society update to acromegaly management guidelines
- (2020) Maria Fleseriu et al. Pituitary
- Multidisciplinary management of acromegaly: A consensus
- (2020) Andrea Giustina et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- PREDICTIVE MARKERS FOR POST-SURGICAL MEDICAL MANAGEMENT OF ACROMEGALY: A SYSTEMATIC REVIEW AND CONSENSUS TREATMENT GUIDELINE
- (2019) Shereen Ezzat et al. Endocrine Practice
- AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
- (2019) Adrian Daly et al. Endocrine Connections
- Potential antitumour activity of pasireotide on pituitary tumours in acromegaly
- (2019) Eva C Coopmans et al. Lancet Diabetes & Endocrinology
- Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands
- (2018) Leandro Kasuki et al. CLINICAL ENDOCRINOLOGY
- MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly
- (2018) Leandro Kasuki et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1–5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues
- (2018) Hande Mefkure Ozkaya et al. Pituitary
- A Consensus Statement on acromegaly therapeutic outcomes
- (2018) Shlomo Melmed et al. Nature Reviews Endocrinology
- Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study
- (2018) Marianne Pavel et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY
- (2018) Michael Buchfelder et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
- (2017) Eva Venegas-Moreno et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas
- (2017) Federico Gatto et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective
- (2017) Iulia Potorac et al. Pituitary
- Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues
- (2017) Wenjuan Liu et al. International Journal of Endocrinology
- Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR
- (2016) Susan L. Samson DRUGS
- Pasireotide for the treatment of acromegaly
- (2016) Luiz Eduardo Wildemberg et al. EXPERT OPINION ON PHARMACOTHERAPY
- Long-Term Remission of Acromegaly after Octreotide Withdrawal Is an Uncommon and Frequently Unsustainable Event
- (2016) Alessandra Casagrande et al. NEUROENDOCRINOLOGY
- Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance
- (2016) Rosa Maria Paragliola et al. Pituitary
- Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers
- (2015) Fredrik Tiberg et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A paradigm shift in the medical treatment of acromegaly: from a ‘trial and error’ to a personalized therapeutic decision-making process
- (2015) Mônica R. Gadelha CLINICAL ENDOCRINOLOGY
- Treatment of acromegaly in the era of personalized and predictive medicine
- (2015) Manuel Puig Domingo CLINICAL ENDOCRINOLOGY
- Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study
- (2015) Donato Iacovazzo et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- A Structural and Functional Acromegaly Classification
- (2015) Daniel Cuevas-Ramos et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
- (2015) Shlomo Melmed et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
- (2015) Annamaria Colao et al. Pituitary
- Acromegaly: An Endocrine Society Clinical Practice Guideline
- (2014) Laurence Katznelson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
- (2014) A. Colao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport Mechanisms
- (2014) Shmuel Tuvia et al. PHARMACEUTICAL RESEARCH
- Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
- (2014) Mônica R Gadelha et al. Lancet Diabetes & Endocrinology
- Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations
- (2013) Marie-Lise Jaffrain-Rea et al. ENDOCRINE-RELATED CANCER
- Octreotide for acromegaly treatment: a reappraisal
- (2013) Andrea Giustina et al. EXPERT OPINION ON PHARMACOTHERAPY
- Somatostatin receptors: From signaling to clinical practice
- (2013) Marily Theodoropoulou et al. FRONTIERS IN NEUROENDOCRINOLOGY
- Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
- (2013) Philippe J. Caron et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression
- (2012) Leandro Kasuki et al. ENDOCRINE-RELATED CANCER
- Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression
- (2012) S. Tuvia et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Somatostatin Analogs Modulate AIP in Somatotroph Adenomas: The Role of the ZAC1 Pathway
- (2012) Harvinder S. Chahal et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly
- (2012) Federico Gatto et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
- (2012) Andrea Giustina et al. PLoS One
- Novel pathway for somatostatin analogs in patients with acromegaly
- (2012) Mônica R. Gadelha et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening
- (2011) Leandro Kasuki Jomori de Pinho et al. Arquivos Brasileiros de Endocrinologia e Metabologia
- Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly
- (2011) Ansgar Heck et al. CLINICAL ENDOCRINOLOGY
- Resistance to Somatostatin Analogs in Acromegaly
- (2011) Annamaria Colao et al. ENDOCRINE REVIEWS
- DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours
- (2011) U Plöckinger et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Place of Cabergoline in Acromegaly: A Meta-Analysis
- (2011) Laure Sandret et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sporadic and genetic forms of paediatric somatotropinoma: a retrospective analysis of seven cases and a review of the literature
- (2011) Cécile Nozières et al. Orphanet Journal of Rare Diseases
- Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study
- (2010) Adrian F. Daly et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study
- (2009) Annamaria Colao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment
- (2009) Ana Paula M. Casarini et al. Pituitary
- Octreotide LARvs.surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study
- (2008) Annamaria Colao et al. CLINICAL ENDOCRINOLOGY
- Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR
- (2008) Giselle F Taboada et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Correlation ofin Vitroandin VivoSomatotropic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy
- (2008) Diego Ferone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now